Advanced Search

 

Study ID Status Title Patient Level Data
EGF20009 Completed A Phase II, Open-Label, Randomized, Parallel-Group Multicenter Trial Comparing Two Schedules of GW572016 as First-Line Monotherapy in Patients with Advanced or Metastatic Breast Cancer
EGF20014 Terminated A Phase 2 Multicenter Trial Comparing Two Schedules of GW572016 as First or Second Line Monotherapy in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer with either Bronchioloalveolar Carcinoma or No Smoking History
EGF30001 Completed A Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Phase III Study of Oral GW572016 in Combination with Paclitaxel in Subjects Previously Untreated or Advanced or Metastatic Breast Cancer
EGF30008 Active, Not Recruiting A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study Comparing GW572016 and Letrozole versus Letrozole in Subjects with Estrogen/Progesterone Receptor-Positive Advanced or Metastatic Breast Cancer
EL110002 Completed A single-centre, randomised, double-blind, double-dummy, placebo-controlled, 3-period crossover study to evaluate the effect of pre-treatment with repeat doses of a new chemical entity (NCE) on the allergen-induced late asthmatic response in subjects with mild to moderate asthma, using…
EL110003 Completed A single centre, randomised, double-blind, placebo-controlled, repeat dose, 4-period cross-over study to evaluate the safety, pharmacokinetics and pharmacodynamics (including the effect on QTc) of a single dose of nebulised salbutamol (5 mg), following repeat-dose administration of a new chemica ...
EL110025 Completed A single-centre, randomised, double-blind, double-dummy, 3-period cross-over study to evaluate the effect of two single doses of inhaled NCE on the subsequent bronchodilator effect of a sub-therapeutic dose of salbutamol (10 mg administered by dosimeter) in patients with moderate asthma.
ELR100710 Completed A Study to Validate Key Therapeutic Targets and Biomarkers during Allergen Exposure in Subjects with Allergic Rhinitis
EMD10007 Completed An Open-Label, Non-Randomised, Pharmacokinetic, Metabolic Disposition and Safety study of a 3 Day Continuous Infusion of GR270773 in Healthy Subjects and Subjects with Hepatic Impairment.
EMD20001 Completed A Prospective, Randomized, Double-blind, Placebo Controlled, Dose Ranging, Multi-Center Study of the Safety and Efficacy of Three Days Continuous Intravenous Infusion of GR270773 in the Treatment of Suspected or Confirmed Gram-negative Severe Sepsis in Adults
EMD20001_1 Completed Long-Term Mortality and Health Outcomes Results from a Prospective, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study of the Safety and Efficacy of Three Days of Continuous IntravenousInfusion of GR270773 in the Treatment of Suspected or Confirmed Gram-Negative Severe ...
EPI40007 Completed The Antiretroviral Pregnancy Registry (APR, Registry)
EPI40048 Completed GlaxoSmithKline International Lamotrigine Pregnancy Registry
EPI40050 Completed The Sumatriptan and Naratriptan Pregnancy Registry
EPI40050_1 Completed The Sumatriptan and Naratriptan Pregnancy Registry
EPI40050_2 Completed The Sumatriptan and Naratriptan Pregnancy Registry
EPI40105 Completed A post-marketing surveillance study of subject-reported adverse events rates for Malarone (atovaquone and proguanil), mefloquine and chloroquine/proguanil, when used for prophylaxis for travel up to 28 days maximum
EPI40404 Completed EPIDEMIOLOGY STUDY: Paroxetine in the First Trimester and the Prevalence of Congenital Malformations (Follow-up to Epidemiology Study: Final Report on Bupropion and Other Antidepressants, including Paroxetine, in Pregnancy and the Occurrence of Cardiovascular and Major Congenital Malformations)
EPV10001 Completed An Open-Label, Randomized, 2-way Cross-over Study to Compare the Steady-State Pharmacokinetics of Lamivudine and Lamivudine Triphosphate Following Lamivudine 300mg Once Daily Versus EPIVIR 150mg Twice a Day in Healthy Volunteers
EPV20001 Completed A Phase II/III 48-Week, Randomized, Double-Blind, Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Lamivudine 300mg QD vs Lamivudine 150mg BID in Combination with Zidovudine 300mg BID and Efavirenz 600mg QD in Antiretroviral-Naïve Adults with HIV-1 Infection. 48-Week Report
EPV40001 Completed Open-Label, Pilot Study To Explore The Early Antiviral Activity And Tolerability Of Abacavir And Epivir When Each Is Administered Once-Daily Within A Triple Combination Regimen Including Abacavir, Epivir And Retrovir Compared to The Triple Combination Regimen Administered Twice-Daily In Antiretr ...
EPZ104057 Completed A 96-Week, Phase IV, Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of EPZICOM Versus TRUVADA Administered in Combination with KALETRA in Antiretroviral-Naive HIV-1 Infected Subjects
EPZ108859 Completed Safety and Efficacy of an Initial Regimen of Atazanavir (ATV) + Ritonavir (/r) + the Abacavir/Lamivudine Fixed-Dose Combination Tablet (ABC/3TC FDC) for 36 weeks followed by Simplification to Atazanavir with ABC/3TC FDC or Maintenance of the Initial Regimen for an Additional 48 weeks in Antiretroviral-Naive HIV-1 Infected HLA-B*5701 Negative Subjects followed by an Optional 60-Week Treatment Extension Phase
E-RHS00176 Completed A pharmacokinetic study comparing two azelastine hydrochloride nasal formulations in a single dose design
ESS 30005 Completed A phase IV, open-label, multicenter study of treatment with TRIZIVIR (abacavir 300mg/lamivudine 150mg/zidovudine 300mg) twice daily and tenofovir 300mg once-daily for 48 weeks in HIV-infected subjects experiencing early virologic failure (ZIAGEN Intensification Protocol)

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.